Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
To identify drugs going off patent next year
— Pharmaceutical ingredient manufacturer, India
To perform literature and patent searches
— Life science entrepreneur, USA
To get patent expiry dates for molecules in South Africa
— Operations manager, India
To get a list of drugs going off patent in USA in the next few years
— Pharmaceutical sales, India
To get information about drug synthesis
— Chemical research, Spain
Generated: May 23, 2017
What is the patent landscape for Thalomid, and when can generic versions of Thalomid launch?
Thalomid is a drug marketed by Celgene and is included in one NDA. There are sixteen patents protecting this drug and three Paragraph IV challenges.| Patents: | 16 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: see list | 1 |
| Bulk Api Vendors: see list | 91 |
| Clinical Trials: see list | 59 |
| Patent Applications: see list | 12,934 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see details |
| DailyMed Link: | THALOMID at DailyMed |
| Physiological Effect | Decreased Immunologically Active Molecule Activity |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Celgene | THALOMID | thalidomide | CAPSULE;ORAL | 020785-004 | Jan 10, 2007 | RX | Yes | No | 7,141,018 | ► Subscribe | ► Subscribe | ||||||||||||||||||
Celgene | THALOMID | thalidomide | CAPSULE;ORAL | 020785-002 | Jan 17, 2003 | RX | Yes | No | 6,755,784 | ► Subscribe | ► Subscribe | ||||||||||||||||||
Celgene | THALOMID | thalidomide | CAPSULE;ORAL | 020785-001 | Jul 16, 1998 | RX | Yes | No | 7,230,012 | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
Celgene | THALOMID | thalidomide | CAPSULE;ORAL | 020785-003 | Jan 17, 2003 | RX | Yes | Yes | 6,315,720 | ► Subscribe | ► Subscribe | ||||||||||||||||||
Celgene | THALOMID | thalidomide | CAPSULE;ORAL | 020785-003 | Jan 17, 2003 | RX | Yes | Yes | 8,589,188 | ► Subscribe | ► Subscribe | ||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Expired Orange Book Patents
Available with subscription
Paragraph IV Activity
Available with subscription
Patent Maintenance
Available with subscription
Non-Orange Book Patents
Available with subscription
International Patents
Available with subscription
Supplementary Protection Certificates
Available with subscription
To prepare patent landscapes and give IP clearance for APIs
— Analyst, India
To do IP due diligence for investment decisions
— Investment manager, South Korea
To identify patent expiration dates
— Medicine sourcing, Malaysia
To get information on when drug patents are set to expire or have expired
— Journalist, UK
To get patent expiry dates for molecules in South Africa
— Operations manager, India
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639
Follow DrugPatentWatch:
